| P2093 | author name string | John D Port | |
| | Nivedita Agarwal | |
| P2860 | cites work | Suicide in schizophrenia | Q22241477 |
| | Schizophrenia | Q22242092 |
| | Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia | Q24646206 |
| | Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder | Q24681663 |
| | Glutamate Carboxypeptidase II Gene Expression in the Human Frontal and Temporal Lobe in Schizophrenia | Q28210167 |
| | Clinical experience with excitatory amino acid antagonist drugs | Q28236051 |
| | Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial | Q28244389 |
| | Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects | Q28276986 |
| | Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies | Q30484459 |
| | Neuroanatomy and neurophysiology in schizophrenia | Q30698640 |
| | Ultrahigh field magnetic resonance imaging and spectroscopy | Q30887511 |
| | Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis | Q31001850 |
| | Simultaneous in vivo spectral editing and water suppression | Q31982014 |
| | 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia | Q32158558 |
| | Chandelier cells and epilepsy | Q33743563 |
| | Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis | Q33767237 |
| | Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia | Q33944802 |
| | Catching up on schizophrenia: natural history and neurobiology | Q34122141 |
| | ??? | Q51512213 |
| | Elevated gamma-aminobutyric acid levels in chronic schizophrenia | Q34142882 |
| | Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. | Q34193383 |
| | Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain | Q34384724 |
| | A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia | Q36070114 |
| | Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction | Q36420372 |
| | Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders | Q36499391 |
| | How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? | Q36644866 |
| | Control of brain glutamine synthesis by NMDA receptors. | Q36664456 |
| | Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem | Q37010792 |
| | Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study | Q37268726 |
| | Creatine abnormalities in schizophrenia and bipolar disorder | Q37312440 |
| | Abnormal excitatory neurotransmitter metabolism in schizophrenic brains | Q41670269 |
| | Optimized glutamate detection at 3T. | Q42175365 |
| | GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study | Q43214682 |
| | Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. | Q43256640 |
| | In vivo 1H NMR spectroscopy of the human brain at 7 T. | Q43732942 |
| | Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers | Q44201512 |
| | N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study | Q44483137 |
| | Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys | Q44502825 |
| | Centenary of Brodmann's map--conception and fate. | Q44577244 |
| | Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. | Q44669007 |
| | Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. | Q44850578 |
| | 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia | Q44915208 |
| | Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. | Q45226292 |
| | Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study | Q45242209 |
| | Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. | Q45999628 |
| | Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. | Q46030016 |
| | Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites | Q46347401 |
| | Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study | Q46600035 |
| | Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia | Q46974035 |
| | Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. | Q48133694 |
| | Reproducibility of GABA measurements using 2D J-resolved magnetic resonance spectroscopy | Q48150778 |
| | Antagonism of phencyclidine-induced hyperactivity by glycine in mice | Q48371174 |
| | Regarding "Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study". | Q48430338 |
| | Measurement of brain glutamate and glutamine by spectrally-selective refocusing at 3 Tesla | Q48591497 |
| | Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy | Q48614993 |
| | In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia | Q48632298 |
| | Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. | Q48732771 |
| | Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. | Q51082286 |
| | The case of the missing glutamine. | Q53079771 |
| | Schizophrenia | Q55868331 |
| P433 | issue | 6 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 1251-1261 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Journal of Magnetic Resonance Imaging | Q15761156 |
| P1476 | title | MR spectroscopy in schizophrenia | |
| P478 | volume | 34 | |